Literature DB >> 22464964

Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants.

Rui Gu1, Cristy Stagnar, Lesya Zaichenko, Arlene I Ramsingh.   

Abstract

Given the limited success of clinical HIV vaccine trials, new vaccine strategies are needed for the HIV pipeline. The present study explored the novel concept that a live enteric virus, with limited disease potential, is a suitable vaccine vector to elicit HIV-specific immune responses in the gut mucosa of immunized mice. Two coxsackievirus B4 (CVB4) vaccine vectors were designed to induce HIV-specific B or T cell responses. A B cell immunogen, CVB4/gp41(2F5), was constructed by expressing an epitope from the membrane proximal external region (MPER) of gp41 as a structural peptide within a surface loop of a capsid protein of CVB4. The T cell immunogen, CVB4/p24(73(3)), was constructed previously by expressing a gag p24 sequence as a non-structural peptide at the amino-terminus of the CVB4 polyprotein. The CVB4/gp41(2F5) recombinant was antigenic in mice and elicited anti-gp41 antibodies in both the mucosal and systemic compartments. The route of immunization affected the antibody response since oral delivery of CVB4/gp41(2F5) induced anti-gp41 antibodies in the mucosal but not in the systemic compartment while parenteral delivery induced anti-gp41 antibodies in both compartments. In contrast, oral immunization with CVB4/p24(73(3)) elicited both mucosal and systemic gag p24-specific T cell responses. Since coxsackieviruses are ubiquitous in the human population, a key question is whether pre-existing vector immunity will inhibit the ability of a CVB4-based vaccine to induce HIV-specific immune responses. We show that pre-existing vector immunity did not preclude the development of mucosal anti-gp41 antibodies or gag p24-specific T cell responses after oral immunization with the CVB4/HIV recombinants. We suggest that the CVB4/HIV recombinants have the potential to be a viable vaccine product because of ease of delivery, safety, immunogenicity, ease of large-scale production, and storage conditions requiring cold-chain temperatures provided by refrigeration.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22464964      PMCID: PMC3356479          DOI: 10.1016/j.vaccine.2012.03.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  52 in total

Review 1.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

Review 2.  Host immune responses to coxsackievirus B3.

Authors:  S Huber
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

3.  HIV vaccine research: the way forward.

Authors:  Anthony S Fauci; Margaret I Johnston; Carl W Dieffenbach; Dennis R Burton; Scott M Hammer; James A Hoxie; Malcolm Martin; Julie Overbaugh; David I Watkins; Adel Mahmoud; Warner C Greene
Journal:  Science       Date:  2008-07-25       Impact factor: 47.728

Review 4.  Toward an AIDS vaccine.

Authors:  Bruce D Walker; Dennis R Burton
Journal:  Science       Date:  2008-05-09       Impact factor: 47.728

Review 5.  Coxsackievirus B epidemiology and public health concerns.

Authors:  M A Pallansch
Journal:  Curr Top Microbiol Immunol       Date:  1997       Impact factor: 4.291

Review 6.  CVB-induced pancreatitis and alterations in gene expression.

Authors:  A I Ramsingh
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

7.  Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.

Authors:  George T Mercier; Pramod N Nehete; Marco F Passeri; Bharti N Nehete; Eric A Weaver; Nancy Smyth Templeton; Kimberly Schluns; Stephanie S Buchl; K Jagannadha Sastry; Michael A Barry
Journal:  Vaccine       Date:  2007-11-05       Impact factor: 3.641

8.  The structure of coxsackievirus B3 at 3.5 A resolution.

Authors:  J K Muckelbauer; M Kremer; I Minor; G Diana; F J Dutko; J Groarke; D C Pevear; M G Rossmann
Journal:  Structure       Date:  1995-07-15       Impact factor: 5.006

9.  Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques.

Authors:  Deborah Heydenburg Fuller; Tim Shipley; Todd M Allen; James T Fuller; Mary S Wu; Helen Horton; Nancy Wilson; Georg Widera; David I Watkins
Journal:  Virology       Date:  2007-04-11       Impact factor: 3.616

Review 10.  Replicating and non-replicating viral vectors for vaccine development.

Authors:  Marjorie Robert-Guroff
Journal:  Curr Opin Biotechnol       Date:  2007-12-11       Impact factor: 9.740

View more
  3 in total

1.  Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease.

Authors:  Arlene I Ramsingh; Kevin Manley; Yinghui Rong; Andrew Reilly; Anne Messer
Journal:  Hum Mol Genet       Date:  2015-08-24       Impact factor: 6.150

Review 2.  Development of replication-competent viral vectors for HIV vaccine delivery.

Authors:  Christopher L Parks; Louis J Picker; C Richter King
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

Review 3.  The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects.

Authors:  Huan Liu; Xiaojie Su; Lulu Si; Lu Lu; Shibo Jiang
Journal:  Protein Cell       Date:  2018-04-17       Impact factor: 14.870

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.